Understanding AI's Expanding Role in Drug Dis...

Voice-based fraud has moved from a fringe security concern to a primary operational risk for financial institutions and enterprise contact centers, and the authentication methods most organizations rely on are no longer adequate. In this episode, Ken Morino, Director of Marketing ...  Afficher plus

The consistency gap in enterprise AI represents a critical failure point where unpredictable system behavior outside of controlled demos threatens to derail executive sponsorship and regulatory compliance. In this episode, Amar Akshat, SVP & Chief Architect at Paysafe, examines h ...  Afficher plus

Bringing new drugs to market is a costly, time-consuming endeavor. On top of that, most medicines fail at some point in the research and development phase. Sarah Guo is joined by Sajith Wickramasekara, co-founder and CEO of Benchling, a company that has not only become the centra ...  Afficher plus

Can AI compress the years long research time of a PhD into seconds? Research scientist Max Jaderberg explores how “AI analogs” simulate real-world lab work with staggering speed and scale, unlocking new insights on protein folding and drug discovery. Drawing on his experience wor ...  Afficher plus

Max Jaderberg and Sergei Yakneen from Isomorphic Labs discuss how AI is enhancing drug discovery by treating biology as an information processing system. They share how advanced AI models like AlphaFold 3 are accelerating the pipeline and paving the way for a future of precision ...  Afficher plus

Techbio is a field combining data, technology and biology to enhance scientific processes — and AI has the potential to supercharge the biopharmaceutical industry further. In this episode of NVIDIA’s AI Podcast, host Noah Kravitz speaks with Chris Gibson, cofounder and CEO of Rec ...  Afficher plus